Adrenal gland
cancer

You are here: 

Follow-up after treatment for adrenal gland cancer

Follow-up after treatment is an important part of cancer care. Follow-up for adrenal gland cancer is often shared among your surgeon, endocrinologist (a doctor who specializes in diseases of the endocrine system) and family doctor. Your healthcare team will work with you to decide on follow-up care to meet your needs.

Don’t wait until your next scheduled appointment to report any new symptoms and symptoms that don’t go away. Tell your healthcare team if you have:

  • weight gain
  • muscle weakness or cramps
  • excessive hair growth on face, arms, chest and back in women
  • mood changes
  • headache
  • rapid heart beat
  • anxiety
  • pain in the abdomen or back
  • diarrhea

Adrenal gland cancer can come back (recur) at any time, so close follow-up is needed.

Schedule for follow-up visits

Follow-up visits for adrenal gland cancer are often scheduled as follows:

  • 2 to 6 weeks after surgery to check hormone levels
  • every 3 months for the first 2 or 3 years
  • every 6 months for the next 5 years

During follow-up visits

During a follow-up visit, your healthcare team will usually ask questions about the side effects of treatment and how you’re coping. Tests are often part of follow-up care. You may have:

  • a physical exam
  • blood chemistry tests to check hormone levels
  • urine tests to check hormone levels
  • imaging tests such as a CT scan, an MRI, a bone scan or a chest x-ray to check for metastases
  • an MIBG scan to check for pheochromocytoma tumours

If the cancer has come back, you and your healthcare team will discuss a plan for your treatment and care.

Questions to ask about follow-up

To make the decisions that are right for you, ask your healthcare team questions about follow-up.

Stories

Researcher Dr Miriam Rosin Dr Miriam Rosin’s research is helping describe the link between HPV and oral cancer.

Learn more

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more